These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31759879)

  • 21. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease.
    Lim YY; Maruff P; Kaneko N; Doecke J; Fowler C; Villemagne VL; Kato T; Rowe CC; Arahata Y; Iwamoto S; Ito K; Tanaka K; Yanagisawa K; Masters CL; Nakamura A
    J Alzheimers Dis; 2020; 77(3):1057-1065. PubMed ID: 32925048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.
    Davatzikos C; Xu F; An Y; Fan Y; Resnick SM
    Brain; 2009 Aug; 132(Pt 8):2026-35. PubMed ID: 19416949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multipredictor risk models for predicting individual risk of Alzheimer's disease.
    Hou XH; Suckling J; Shen XN; Liu Y; Zuo CT; Huang YY; Li HQ; Wang HF; Tan CC; Cui M; Dong Q; Tan L; Yu JT;
    J Transl Med; 2023 Oct; 21(1):768. PubMed ID: 37904154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study.
    Van Hooren RWE; Riphagen JM; Jacobs HIL;
    Alzheimers Res Ther; 2018 Aug; 10(1):88. PubMed ID: 30153858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease.
    Pfeil J; Hoenig MC; Doering E; van Eimeren T; Drzezga A; Bischof GN;
    Neurobiol Aging; 2021 Oct; 106():119-129. PubMed ID: 34284259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
    Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
    Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H; Lyu D; Jia J;
    J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
    Langbaum JB; Ellison NN; Caputo A; Thomas RG; Langlois C; Riviere ME; Graf A; Lopez Lopez C; Reiman EM; Tariot PN; Hendrix SB
    Alzheimers Res Ther; 2020 May; 12(1):66. PubMed ID: 32460855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
    Vannini P; Amariglio R; Hanseeuw B; Johnson KA; McLaren DG; Chhatwal J; Pascual-Leone A; Rentz D; Sperling RA
    Neuropsychologia; 2017 May; 99():343-349. PubMed ID: 28385579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.
    Parnetti L; Chipi E; Salvadori N; D'Andrea K; Eusebi P
    Alzheimers Res Ther; 2019 Jan; 11(1):7. PubMed ID: 30646955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.
    Elman JA; Panizzon MS; Gustavson DE; Franz CE; Sanderson-Cimino ME; Lyons MJ; Kremen WS;
    Biol Psychiatry; 2020 May; 87(9):819-828. PubMed ID: 32067693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.